Clinical trials: Weight Management
Bipolar I Disorder, Schizophrenia
Study in Adolescents With Schizophrenia or Bipolar Disorder
Open-label safety study of oral olanzapine treatment in adolescents, aged 13 to 17 years, with bipolar I disorder (manic or mixed episodes) or schizophrenia.
- Trial name
- NCT00982020
- Testing
- Olanzapine, Standard behavioral weight intervention, Intense behavioral weight intervention
- Where
- 14 sites in United States, Poland and 2 more
- Volunteers
- 203 people
- Sponsor
- Eli Lilly and Company
Healthy Participants
Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese
A study in healthy male and female participants of non-childbearing potential who are overweight or obese.
- Trial name
- NCT05511025
- Testing
- AZD6234, Acetaminophen
- Where
- 2 sites in United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Overweight, Obesity
Weight and Metabolic Management Study
The goal of this clinical trial is to learn whether elénzia CONTROL®, a nutritional supplement, can support weight management in adults who have either never used GLP-1 weight-loss medications or have recently stopped using them.
- Conditions
- Overweight, Obesity, Weight Maintenance
- Trial name
- WMMS (NCT07789223)
- Testing
- elénzia CONTROL®
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- Elenzia
Obesity, Overweight
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM.
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
- Trial name
- NCT07654374
- Testing
- aleniglipron
- Where
- 74 sites in United States
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ASC35 injection
- Trial name
- NCT07842640
- Testing
- ASC35 Injection B, for subcutaneous use, Tirzepatide
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharma (China) Co., Limited
Overweight, Obesity
A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity
This study looks at NNC0247-0829 (a potential new medicine) for weight management in people with overweight or obesity. The study looks at how NNC0247-0829 works in the body.
- Trial name
- NCT04010786
- Testing
- NNC0247-0829
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Novo Nordisk A/S
Metabolic Health, Weight Management
A Clinical Trial to Evaluate the Effects of A Supplement on Supporting Signs of Metabolic Health
This study evaluates the effects of the Love Wellness supplement Hello Burn Activate on supporting metabolic health in adult females.
- Conditions
- Metabolic Health, Weight Management, Body Confidence, Gut Health
- Trial name
- NCT07765394
- Testing
- Hello Burn Activate
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Love Wellness
Overweight, Obesity
A Research Study to Compare Two Different Forms of Once-weekly Semaglutide in Two Different Injection Pens
The study will look at how 2 different semaglutide versions reach and stay in the blood after injection. The study aims to show similar levels of semaglutide in the blood when using the different semaglutide versions.
- Trial name
- NCT04238962
- Testing
- Semaglutide (administered by DV3396 pen-injector), Semaglutide (administered by PDS290 pen-injector)
- Where
- Germany
- Volunteers
- 111 people
- Sponsor
- Novo Nordisk A/S
Obesity
Study of Five Different Methods Of Delivering A Lifestyle Modification Program for Weight Loss
The aim of the study was to compare 5 methods of delivering a weight loss lifestyle modification program to obese patients on a background of sibutramine.
- Trial name
- NCT00471172
- Testing
- Face-to-face counseling by a dietitian (months 1-3: weekly, months 4-6: every other week), Face-to-face counseling by a dietitian (monthly), Counseling by a dietitian via telephone (months 1-3: weekly, months 4-6: every other week)
- Where
- 12 sites in United States
- Volunteers
- 350 people
- Sponsor
- Pfizer
Obesity
Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss
Multiple pathways including peripheral and central hormones and neurotransmitters are involved in the regulation of food intake and body weight. One of the most studied pathways involves the melanocortin receptor.
- Trial name
- NCT00779519
- Testing
- TTP435
- Where
- 12 sites in United States, Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- vTv Therapeutics
Overweight, Metabolic Health
Study to Evaluate the Efficacy of an Avocado Dietary Supplement
This 16-week, randomized, triple-blinded, placebo-controlled study evaluates the effects of an avocado dietary supplement (Metavo) on healthy weight and blood glucose management in overweight adults.
- Conditions
- Overweight, Metabolic Health, Insulin Resistance
- Trial name
- METAVO-ONE (NCT07354308)
- Testing
- Metavo Supplement
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- SP Nutraceuticals Inc.
Obesity
Awareness, Care & Treatment In Obesity Management
ACTION France is a cross-sectional, observational, descriptive, and exploratory survey-based study without collection of laboratory data. The study is not related to any specific treatment options or pharmaceutical product.
- Trial name
- ACTION-France (NCT05690789)
- Testing
- No treatment given
- Where
- France
- Volunteers
- 1,688 people
- Sponsor
- Novo Nordisk A/S
Body Weight Management
A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Study of SHR-1179 Injection in Participants With Obesity
This study is a single-center, randomized, double-blind, dose-escalation, placebo-parallel-controlled Phase I clinical trial. The primary objective is to evaluate the safety and tolerability of a single subcutaneous injection of…
- Trial name
- NCT07826364
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Overweight, Obesity
Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.
This study will look at the change in body weight in people taking NNC0174-0833, liraglutide and "dummy" medicine, from the start to the end of the study.
- Trial name
- NCT03856047
- Testing
- NNC0174-0833, Liraglutide 3.0 mg
- Where
- 54 sites in United States, Canada and 8 more
- Volunteers
- 706 people
- Sponsor
- Novo Nordisk A/S
Obesity
Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics
A recently completed clinical drug interaction study of CP-945,598 with ketoconazole, a potent CYP3A inhibitor, showed that coadministration of CP-945,598 with ketoconazole results in an approximately 5-fold increase in…
- Trial name
- NCT00645463
- Testing
- CP-945,598
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overweight and Obesity, Metabolic Syndrome
Using Signos mHealth Platform in Adults for Weight Management
Metabolic syndrome and resulting downstream health effects remains a growing health concern. In published trials, the use of continuous glucose monitoring (CGM) assists behavioral changes efforts, leading to improved adherence…
- Conditions
- Overweight and Obesity, Metabolic Syndrome, Weight Loss
- Trial name
- SWEET (NCT06214221)
- Testing
- Signos System, Standard Lifestyle Education
- Where
- 5 sites in United States
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Signos Inc
Weight Loss
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics…
- Trial name
- NCT07104383
- Testing
- VK2735
- Where
- 127 sites in United States, Puerto Rico
- Volunteers
- 1,100 people
- Sponsor
- Viking Therapeutics, Inc.
Chronic Weight Management
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity
This randomized, double-blind, placebo-controlled single ascending dose (SAD)/ multiple ascending dose (MAD) study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASC30 injection
- Trial name
- NCT06679959
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Ascletis Pharma (China) Co., Limited
Obesity
A Study to Learn How Different Amounts of the Study Medicine Danuglipron Are Taken up Into the Blood in Otherwise Healthy Adults With Overweight or Obesity
The purpose of this study is to learn the following about the study medicine, danuglipron, after multiple days of dosing in healthy adults who are overweight or obese: how the study medicine, danuglipron, is taken up into the…
- Trial name
- NCT06568731
- Testing
- Danuglipron
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Pfizer
Metabolic Syndrome, Obesity
Effect of Irvingia Gabonensis (Bush Mango)on Parameters Associated With Metabolic Syndrome
The study investigated the use and efficacy of the seeds of African bush mango (Irvingia gabonensis)to control body weight, blood lipids and hormones in overweight and obese people.
- Conditions
- Metabolic Syndrome, Obesity, Dyslipidemia
- Trial name
- NCT00645775
- Testing
- IGOB131
- Where
- Cameroon
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Gateway Health Alliance